Compare Moderna, Inc. (MRNA) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Invesco Preferred ETF — how do they compare? Moderna, Inc. trades at $137.65 (market cap $56.02B), while Invesco Preferred ETF trades at $10.38. The key difference: Moderna, Inc. is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | PGX | |
|---|---|---|
Market Cap | $56.02B | — |
Sector | Health | — |
52-Week High | $174.38 | $11.87 |
52-Week Low | $22.36 | $10.46 |
Enterprise Value | $52.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
PGX trades at $10.49 with no change in the last 24 hours. Technical indicators show a bearish trend from moving averages but bullish signals from oscillators, with support at $10 and resistance at $11. Recent corporate actions include dividends declared for H1-26 and H2-26, though key financial ratios are unavailable for fundamental assessment.
The outlook remains uncertain due to limited financial data. Opportunities include dividend income, but risks stem from the lack of transparency in earnings and valuation metrics. Investors should seek updated SEC filings for a clearer picture of the company's health and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
